Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 6/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ITK | Q08881 | 2/20 | 0.34 |
| ▸ | BMX | P51813 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22625600 | 0.91 | ALDH1A1 (0.37) | BTKBLKALDH1A1EGFRJAK3 | |
| SCHEMBL22625634 | 0.73 | LCK (0.45) | BTKBLKEGFRJAK3BMX | |
| SCHEMBL22652928 | 0.72 | KDR (0.44) | BTKBLKALDH1A1EGFRJAK3 | |
| SCHEMBL22625605 | 0.72 | RAF1 (0.49) | BTKBLKALDH1A1EGFRJAK3 | |
| SCHEMBL22652926 | 0.67 | ALDH1A1 (0.42) | BTKBLKALDH1A1EGFRJAK3 | |
| SCHEMBL22625559 | 0.66 | RAF1 (0.43) | BTKBLKALDH1A1EGFRJAK3 | |
| SCHEMBL26165618 | 0.66 | ALDH1A1 (0.39) | ALDH1A1MEN1MAPTKMT2ASCD | |
| SCHEMBL20023001 | 0.64 | ALDH1A1 (0.56) | ALDH1A1MEN1MAPTKMT2ARAB9A | |
| SCHEMBL22625561 | 0.63 | KDR (0.59) | BTKALDH1A1EGFRJAK3RAB9A | |
| SCHEMBL24367126 | 0.62 | ALDH1A1 (0.55) | BTKALDH1A1MAPTKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| US-10927111-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | BTK 24/4885BLK 70/4885ALDH1A1 3044/4885 |
| US-10927111-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | BTK 24/4885BLK 70/4885ALDH1A1 3044/4885 |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | BTK 24/4885BLK 70/4885ALDH1A1 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.